Trends in Retinopathy of Prematurity Screening and Treatment: 2008–2018
- 1 June 2021
- journal article
- research article
- Published by American Academy of Pediatrics (AAP) in PEDIATRICS
- Vol. 147 (6)
- https://doi.org/10.1542/peds.2020-039966
Abstract
BACKGROUND AND OBJECTIVES: Retinopathy of prematurity (ROP) is the leading avoidable and treatable cause of childhood blindness in the United States. The objective of this study was to evaluate trends of ROP screening, incidence, and treatment in US NICUs over the last 11 years. METHODS: Using standardized data submitted by NICUs from US Vermont Oxford Network member hospitals from 2008 to 2018 on very low birth weight infants hospitalized at the recommended age for ROP screening, we assessed trends in the proportion of eligible infants who received ROP screening, incidence, and treatment of ROP using logistic regression models. RESULTS: This study included 381 065 very low birth weight infants at 819 US NICUs participating in Vermont Oxford Network. Over time, more eligible infants received ROP screening (89% in 2008 to 91% in 2018, trend P < .001). Among those screened, overall ROP (stages 1–5, 37% in 2008 to 32% in 2018), severe ROP (stages 3–5, 8% in 2008 to 6% in 2018), and retinal ablation (6% in 2008 to 2% in 2018) declined and anti–vascular endothelial growth factor injections (1% in 2012 to 2% in 2018) increased (all trend P < .001). CONCLUSIONS: Among US hospitals from 2008 to 2018, the proportion of ROP screening among infants hospitalized at the recommended age increased, less overall and severe ROP were reported, less retinal ablation was performed, and more anti–vascular endothelial growth factor treatment was used. Despite increased ROP screening over time, 10% of infants were not screened, representing an opportunity for improvement in health care delivery.This publication has 18 references indexed in Scilit:
- A systematic review and meta-analysis to revise the Fenton growth chart for preterm infantsBMC Pediatrics, 2013
- An update on progress and the changing epidemiology of causes of childhood blindness worldwideJournal of American Association for Pediatric Ophthalmology and Strabismus, 2012
- Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of PrematurityThe New England Journal of Medicine, 2011
- Incidence of Retinopathy of Prematurity in the United States: 1997 through 2005American Journal of Ophthalmology, 2009
- Neonatologists' Practices and Experiences in Arranging Retinopathy of Prematurity Screening ServicesPEDIATRICS, 2007
- The Incidence and Course of Retinopathy of Prematurity: Findings From the Early Treatment for Retinopathy of Prematurity StudyPEDIATRICS, 2005
- The International Classification of Retinopathy of Prematurity RevisitedAmerican Journal of Ophthalmology, 2005
- Revised Indications for the Treatment of Retinopathy of PrematurityJAMA Ophthalmology, 2003
- Incidence and Early Course of Retlnonathy of PrematurityOphthalmology, 1991
- Multicenter Trial of Cryotherapy for Retinopathy of PrematurityAmerican Journal of Ophthalmology, 1988